

# Suvankar Pal

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9634961/publications.pdf>

Version: 2024-02-01

53  
papers

1,976  
citations

361413

20  
h-index

254184

43  
g-index

57  
all docs

57  
docs citations

57  
times ranked

2910  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report. <i>Lancet, The</i> , 2006, 368, 2061-2067.	13.7	374
2	Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial. <i>Lancet Neurology, The</i> , 2009, 8, 334-344.	10.2	226
3	ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS. <i>Neurology</i> , 2018, 91, e1370-e1380.	1.1	170
4	Influence of Intracerebral Hemorrhage Location on Incidence, Characteristics, and Outcome. <i>Stroke</i> , 2015, 46, 361-368.	2.0	142
5	A systematic review and meta-analysis of retinal nerve fiber layer change in dementia, using optical coherence tomography. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 136-143.	2.4	133
6	Functional (Psychogenic) Cognitive Disorders: A Perspective from the Neurology Clinic. <i>Journal of Alzheimer's Disease</i> , 2015, 48, S5-S17.	2.6	83
7	The importance of ongoing international surveillance for Creutzfeldt-Jakob disease. <i>Nature Reviews Neurology</i> , 2021, 17, 362-379.	10.1	69
8	TDP-43 as a potential biomarker for amyotrophic lateral sclerosis: a systematic review and meta-analysis. <i>BMC Neurology</i> , 2018, 18, 90.	1.8	63
9	A systematic review and meta-analysis of <sup>18</sup> F-labeled amyloid imaging in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 5-13.	2.4	59
10	Systematic review of the diagnostic utility of SPECT imaging in dementia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2013, 263, 539-552.	3.2	56
11	Executive, language and fluency dysfunction are markers of localised TDP-43 cerebral pathology in non-demented ALS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 149-157.	1.9	54
12	The diagnostic utility of EEG in early-onset dementia: a systematic review of the literature with narrative analysis. <i>Journal of Neural Transmission</i> , 2014, 121, 59-69.	2.8	53
13	Improved PCR based methods for detecting C9orf72 hexanucleotide repeat expansions. <i>Molecular and Cellular Probes</i> , 2016, 30, 218-224.	2.1	42
14	Non-Motor Symptoms Profile and Burden in Drug Naïve Versus Long-Term Parkinson's Disease Patients. <i>Journal of Parkinson's Disease</i> , 2014, 4, 541-547.	2.8	41
15	Changing epidemiology of motor neurone disease in Scotland. <i>Journal of Neurology</i> , 2019, 266, 817-825.	3.6	40
16	Genetic epidemiology of motor neuron disease-associated variants in the Scottish population. <i>Neurobiology of Aging</i> , 2017, 51, 178.e11-178.e20.	3.1	37
17	Clinical trials in amyotrophic lateral sclerosis: a systematic review and perspective. <i>Brain Communications</i> , 2021, 3, fcab242.	3.3	32
18	Validation of Revised International Creutzfeldt-Jakob Disease Surveillance Network Diagnostic Criteria for Sporadic Creutzfeldt-Jakob Disease. <i>JAMA Network Open</i> , 2022, 5, e2146319.	5.9	28

#	ARTICLE	IF	CITATIONS
19	Phenotypic diversity of genetic Creutzfeldtâ€“Jakob disease: a histo-molecular-based classification. <i>Acta Neuropathologica</i> , 2021, 142, 707-728.	7.7	24
20	The brief Dimensional Apathy Scale: A short clinical assessment of apathy. <i>Clinical Neuropsychologist</i> , 2020, 34, 423-435.	2.3	22
21	A systematic review of neuropsychiatric and cognitive assessments used in clinical trials for amyotrophic lateral sclerosis. <i>Journal of Neurology</i> , 2021, 268, 4510-4521.	3.6	22
22	A systematic review of non-motor symptom evaluation in clinical trials for amyotrophic lateral sclerosis. <i>Journal of Neurology</i> , 2022, 269, 411-426.	3.6	21
23	Clinical audit research and evaluation of motor neuron disease (CARE-MND): a national electronic platform for prospective, longitudinal monitoring of MND in Scotland. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2019, 20, 242-250.	1.7	19
24	Investigating Domain-Specific Cognitive Impairment Among Patients With Multiple Sclerosis Using Touchscreen Cognitive Testing in Routine Clinical Care. <i>Frontiers in Neurology</i> , 2018, 9, 331.	2.4	17
25	Relationship between neuropsychiatric disorders and cognitive and behavioural change in MND. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 245-253.	1.9	15
26	Reliability and validity of the brief dimensional apathy scale. <i>Archives of Clinical Neuropsychology</i> , 2020, 35, 539-544.	0.5	13
27	Cerebrospinal fluid cytotoxicity in amyotrophic lateral sclerosis: a systematic review of in vitro studies. <i>Brain Communications</i> , 2020, 2, fcaa121.	3.3	10
28	40 Years of CSF Toxicity Studies in ALS: What Have We Learnt About ALS Pathophysiology?. <i>Frontiers in Molecular Neuroscience</i> , 2021, 14, 647895.	2.9	10
29	Motor Neuron Disease Systematic Multi-Arm Adaptive Randomised Trial (MND-SMART): a multi-arm, multi-stage, adaptive, platform, phase III randomised, double-blind, placebo-controlled trial of repurposed drugs in motor neuron disease. <i>BMJ Open</i> , 2022, 12, e064173.	1.9	10
30	Trials for neurodegenerative diseases: time to innovate. <i>Lancet Neurology, The</i> , 2021, 20, 984.	10.2	9
31	Incidental Findings Identified on Head MRI for Investigation of Cognitive Impairment: A Retrospective Review. <i>Dementia and Geriatric Cognitive Disorders</i> , 2019, 48, 123-130.	1.5	8
32	Bilateral lower limb weakness in acute severe ulcerative colitis. <i>Lancet, The</i> , 2016, 388, 101-102.	13.7	7
33	Surveillance for variant CJD: should more children with neurodegenerative diseases have autopsies?. <i>Archives of Disease in Childhood</i> , 2019, 104, 360-365.	1.9	7
34	Application of telehealth for comprehensive Creutzfeldt-Jakob disease surveillance in the United Kingdom. <i>Journal of the Neurological Sciences</i> , 2021, 420, 117221.	0.6	7
35	An epidemiological profile of dysarthria incidence and assistive technology use in the living population of people with MND in Scotland. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2020, 21, 116-122.	1.7	6
36	The immediate impact of the COVID-19 pandemic on motor neuron disease services and mortality in Scotland. <i>Journal of Neurology</i> , 2021, 268, 2038-2040.	3.6	6

#	ARTICLE	IF	CITATIONS
37	Prospective observational cohort study of factors influencing trial participation in people with motor neuron disease (FIT-participation-MND): a protocol. <i>BMJ Open</i> , 2021, 11, e044996.	1.9	6
38	Validation of The Edinburgh cognitive and behavioural ALS screen (ECAS) in behavioural variant frontotemporal dementia and Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 1576-1587.	2.7	5
39	The Prevalence and Management of Saliva Problems in Motor Neuron Disease: A 4-Year Analysis of the Scottish Motor Neuron Disease Register. <i>Neurodegenerative Diseases</i> , 2020, 20, 147-152.	1.4	5
40	Progressive unsteadiness in a 68-year-old man with longstanding abdominal pain and altered bowel habit. <i>Practical Neurology</i> , 2009, 9, 210-220.	1.1	4
41	Excellent reliability of the ALSFRS-R administered via videoconferencing: A study of people with motor neuron disease in Scotland. <i>Journal of the Neurological Sciences</i> , 2020, 416, 116991.	0.6	4
42	Riluzole prescribing, uptake and treatment discontinuation in people with amyotrophic lateral sclerosis in Scotland. <i>Journal of Neurology</i> , 2020, 267, 2459-2461.	3.6	4
43	Impact of the COVID-19 pandemic on Creutzfeldt-Jakob disease surveillance and patient care in the United Kingdom. <i>European Journal of Neurology</i> , 2021, , .	3.3	4
44	Screening for cognitive impairment among patients with neuromyelitis optica using touchscreen cognitive testing in routine clinical care. <i>Journal of Neurology</i> , 2019, 266, 2571-2572.	3.6	2
45	The prevalence of multimorbidity and its impact on survival in people with motor neuron disease. <i>European Journal of Neurology</i> , 2021, 28, 2756-2765.	3.3	2
46	31st Advanced Clinical Neurology Course, Edinburgh 2009: progressive cognitive impairment, behavioural change and upper motor neuron signs in a 57-year-old woman. <i>Practical Neurology</i> , 2011, 11, 71-80.	1.1	1
47	070... A pilot study assessing choroidal thickness in frontotemporal dementia and motor neuron disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, A122.2-A122.	1.9	1
48	A challenging case of double vision and altered facial sensation. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 539-540.	1.9	0
49	P2-190: Detecting profiles of cognitive performance in dementia syndromes and parkinson's disease using brief computerized cognitive tests. , 2015, 11, P565-P565.		0
50	Clinicopathological case: progressive somnolence and dementia in an accountant: when the shine rubs off the gold standard. <i>Practical Neurology</i> , 2018, 18, 505-512.	1.1	0
51	Understanding the risk of incidental findings: A qualitative study of people with cognitive symptoms. <i>Journal of the Neurological Sciences</i> , 2020, 419, 117203.	0.6	0
52	Non-white cases of sporadic Creutzfeldt-Jakob disease: A 28-year review of United Kingdom National Surveillance Data. <i>Journal of the Neurological Sciences</i> , 2021, 424, 117416.	0.6	0
53	The assessment of visually guided reaching in prodromal Alzheimer's disease. <i>Journal of Vision</i> , 2020, 20, 1059.	0.3	0